Tofacitinib tissue exposure correlates with endoscopic outcome
Presenting the first patient data demonstrating a relationship between mucosal exposure and clinical response in ulcerative colitis patients.
Clinical collaborators from IBD Leuven, Amsterdam UMC, and Biora presented patient data demonstrating a significant positive correlation between mucosal exposure and endoscopic improvement in patients with moderate to severe ulcerative colitis who were treated with tofacitinib.
What did we find?
Demonstrated for the first time a mucosal exposure-response relationship with tofacitinib in ulcerative colitis.
Identified pSTAT3/STAT3 ratio as a potential molecular marker to track response, directly linked to the mechanism of action of tofacitinib.
This data supports the hypothesis that targeted delivery of tofacitinib to the site of disease has the potential to improve patient outcomes.
Oral presentation at Digestive Disease Week 2022, May 21, 2022.
Oral presentation at the 34th edition of the Belgian Week of Gastroenterology, February 9, 2022.
Poster presentation at the 17th Congress of the European Crohn’s and Colitis Organisation (ECCO), February 18, 2022.
Connect with us